BioCardia, Inc. (NASDAQ:BCDA) Director Andrew Scott Blank Buys 72,289 Shares

BioCardia, Inc. (NASDAQ:BCDAGet Free Report) Director Andrew Scott Blank acquired 72,289 shares of the business’s stock in a transaction dated Monday, June 30th. The shares were bought at an average price of $2.08 per share, for a total transaction of $150,361.12. Following the completion of the acquisition, the director owned 346,023 shares in the company, valued at approximately $719,727.84. This trade represents a 26.41% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

BioCardia Price Performance

Shares of BCDA stock opened at $2.08 on Thursday. The firm has a market cap of $10.77 million, a P/E ratio of -0.89 and a beta of 0.81. BioCardia, Inc. has a 1-year low of $1.63 and a 1-year high of $4.66. The firm’s 50-day simple moving average is $2.29 and its 200-day simple moving average is $2.29.

BioCardia (NASDAQ:BCDAGet Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.20). Analysts expect that BioCardia, Inc. will post -3.52 earnings per share for the current fiscal year.

Institutional Trading of BioCardia

A number of institutional investors and hedge funds have recently bought and sold shares of BCDA. CM Management LLC acquired a new stake in BioCardia during the 4th quarter worth approximately $54,000. Geode Capital Management LLC increased its position in BioCardia by 110.3% during the 4th quarter. Geode Capital Management LLC now owns 30,987 shares of the company’s stock worth $68,000 after purchasing an additional 16,251 shares in the last quarter. Finally, Brown Advisory Inc. acquired a new stake in BioCardia during the 1st quarter worth approximately $90,000. Institutional investors and hedge funds own 20.57% of the company’s stock.

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.

Recommended Stories

Insider Buying and Selling by Quarter for BioCardia (NASDAQ:BCDA)

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.